| 0.7351 -0.006 (-0.86%) | 12-12 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.92 | 1-year : | 1.08 |
| Resists | First : | 0.79 | Second : | 0.92 |
| Pivot price | 0.67 |
|||
| Supports | First : | 0.66 | Second : | 0.58 |
| MAs | MA(5) : | 0.73 |
MA(20) : | 0.66 |
| MA(100) : | 0.59 |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 79.2 |
D(3) : | 87.4 |
| RSI | RSI(14): 63.6 |
|||
| 52-week | High : | 1.08 | Low : | 0.21 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ RLYB ] has closed below upper band by 17.6%. Bollinger Bands are 44.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.74 - 0.75 | 0.75 - 0.75 |
| Low: | 0.71 - 0.72 | 0.72 - 0.72 |
| Close: | 0.73 - 0.74 | 0.74 - 0.74 |
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
Thu, 06 Nov 2025
Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates - Business Wire
Thu, 25 Sep 2025
Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study - Business Wire
Thu, 25 Sep 2025
Rallybio completes first cohort dosing in RLYB116 C5 inhibitor study - Investing.com
Thu, 07 Aug 2025
Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates - Yahoo Finance
Thu, 10 Jul 2025
We're Keeping An Eye On Rallybio's (NASDAQ:RLYB) Cash Burn Rate - simplywall.st
Tue, 08 Jul 2025
Why Is Microcap Rallybio Stock Trading Higher On Tuesday? - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 42 (M) |
| Held by Insiders | 2.032e+007 (%) |
| Held by Institutions | 4 (%) |
| Shares Short | 284 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.314e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 266.5 % |
| Return on Equity (ttm) | -28.4 % |
| Qtrly Rev. Growth | 674000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -35 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.52 |
| Dividend | 0 |
| Forward Dividend | 174570 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|